Project Grant R61AG090358
Award Date
1/15/25
Completion Date
12/31/26
Dollars Obligated
$735K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
The National Institute on Aging (NIA) awarded a $810,596 Project Grant under the Aging Research program (CFDA 93.866) to New York University (NYU) to develop a novel chimeric antigen receptor (CAR) macrophage (MI) therapy for Alzheimer's disease (AD). The objectives are to create "off-the-shelf" human induced pluripotent stem cell-derived MIs that can be genetically programmed to target and clear amyloid-beta deposits, a key pathological hallmark of AD. The 2-year award period runs...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $374,000.00 to the University of California, Los Angeles (UCLA) to develop and evaluate a novel hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease (AD). The key objectives are to: 1) Optimize an AB-targeting CAR-macrophage (CAR-M) therapy for in vitro efficacy against AB aggregates and reducing neuroinflammation, and 2) Investigate the safety...
This federal Project Grant award from the National Institute on Aging's (NIA) Aging Research Program (CFDA 93.866) provides $834,627 to the University of Florida to develop a novel "theranostic" (therapeutic and diagnostic) chimeric antigen receptor (CAR) T cell platform for targeting senescent cells associated with Alzheimer's disease and related dementias. The key products to be delivered include: A senescence-responsive theranostic abscisic acid (ABA) inducer that can selectively...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $728,370 to The Washington University to develop engineered T cell approaches for Alzheimer's disease. The goal is to design and develop "CARDINAL" (CAR Disease Interventions for Alzheimer's) T cells that are programmed to expand and persist at the site of Alzheimer's pathology, and release neuroprotective payloads such as IL-4 and BDNF to support neuronal function and improve...
This federal Project Grant award from the National Institute on Aging (NIA), under CFDA Program 93.866 Aging Research, provides $613,571 to the University of Chicago to develop an in vivo gene therapy approach for treating Alzheimer's disease. The project aims to engineer chimeric antigen receptor (CAR)-expressing microglia that can recognize and clear amyloid-beta plaques, a key pathological hallmark of Alzheimer's. The researchers will package mRNA encoding anti-amyloid-beta CAR constructs and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $433,125 will fund a study to investigate the relationship between microglia, neurons, and tau pathology in Alzheimer's disease. The research will utilize a novel model system of microglial co-cultures with hippocampal assembloids derived from patient-derived induced pluripotent stem cell (iPSC) lines with MAPT mutations and healthy controls. The goal is to explore how bidirectional changes...
This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $704,198.00 to Trustees of Dartmouth College from December 1, 2024 to November 30, 2026 to develop chimeric antigen receptor (CAR) T regulatory cells (Tregs) that target aggregated amyloid-beta, a key hallmark of Alzheimer's disease (AD). The goal is to enhance the persistence of these CAR Tregs in the central nervous system to help rebalance cerebral immunity, promote amyloid-beta...
This $614,424 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to better understand the role of microglia, the brain's immune cells, in the development of Alzheimer's disease (AD). The University of Washington (UW) will leverage novel explainable AI techniques and human induced pluripotent stem cell (iPSC) models to uncover subtle microglial changes that occur early in AD progression. Specifically, UW will expose microglia-neuron iPSC cultures to...
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...